BUSINESS General We were incorporated in Delaware on November 27, 2001. 8226; Effective for nocturnal use. The CARES Act implemented the relief effective May 1, 2020 through December 31, 2020. The supplier may not arbitrarily issue new equipment. If the equipment malfunctions, we must repair or replace the equipment. In September 2019, we appealed to CMS, and in January 2020 our appeal was denied. We may not be able to compete effectively against these organizations. We obtained 510(k) clearance for the Inogen At Home system on June 20, 2014. In addition, we are subject to certain state laws regarding professional licensure. We believe that we are in compliance with such laws. We own a trademark registration for the Inogen design in China. Bart Sanford has served as our Executive Vice President, Operations since September 2018. We also plan to incorporate the TAV technology directly into our oxygen concentrators. As of February 5, 2021, there were 83 co-sponsors on this bill. We do not have long-term supply contracts with many of our third-party suppliers. We leverage various third parties to sell our products and conduct our business abroad. This competitive environment could result in increased labor costs. We have incurred remedial, legal and other costs in connection with this incident. Additionally, the FDA and other regulatory authorities have broad enforcement powers. This is commonly known as a beneficiary inducement. Regulatory requirements under Proposition 65 could adversely affect our business.